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Bordetella (B.) pertussis resurgence affects not only the unvaccinated, but also the
vaccinated population. Different vaccines are available, however, it is currently unknown
whether the type of childhood vaccination has an influence on antibody responses
following a B. pertussis infection later in life. Therefore, the study aim was to profile
serum antibody responses in young adults with suspected B. pertussis infections,
immunized during childhood with either whole-cell (wPV) or monocomponent acellular
pertussis (aPV) vaccines. Serum anti-pertussis toxin (PTx) IgG antibody levels served
as an indicator for a recent B. pertussis infection. Leftover sera from a diagnostic
laboratory from 36 Danish individuals were included and divided into four groups based
on immunization background (aPV vs. wPV) and serum anti-PTx IgG levels (– vs.
+). Pertussis-specific IgG/IgA antibody levels and antigen specificity were determined
by using multiplex immunoassays (MIA), one- and two-dimensional immunoblotting (1
& 2DEWB), and mass spectrometry. Besides enhanced anti-PTx levels, wPV(+) and
aPV(+) groups showed increased IgG and IgA levels against pertactin, filamentous
hemagglutinin, fimbriae 2/3, and pertussis outer membrane vesicles (OMV). In the
wPV(–) and aPV(–) groups, only low levels of anti-OMV antibodies were detected.
1DEWB demonstrated that antibody patterns differed between groups but also between
individuals with the same immunization background and anti-PTx levels. 2DWB analysis
for serum IgG revealed 133 immunogenic antigens of which 40 were significantly
different between groups allowing to differentiate wPV(+) and aPV(+) groups. Similarly,
for serum IgA, 7 of 47 immunogenic protein spots were significantly different. This study
demonstrated that B. pertussis infection-induced antibody responses were distinct on
antigen level between individuals with either wPV or aPV immunization background.
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Importantly, only 2DEWB and not MIA could detect these differences indicating the
potential of this method. Moreover, in individuals immunized with an aPV containing only
PTx in childhood, the infection-induced antibody responses were not limited to PTx alone.
Keywords: Bordetella pertussis, vaccination, acellular pertussis vaccine, whole-cell pertussis vaccine,
2-dimensional electrophoresis (2DE), antibody specificity, infection-induced response, pertussis toxin (PTx)
INTRODUCTION
Pertussis vaccines have been in use since the middle of
the twentieth century and have successfully decreased the
incidence of pertussis. However, despite worldwide pertussis
immunizations, an increase in pertussis cases has been observed
both in developing countries that are using inactivated whole-
cell pertussis vaccines (wPV) as well as in industrialized
countries that mainly use acellular pertussis vaccines (aPV)
(1). Comparisons of incidences between countries are however
virtually impossible (2). The observed increases in pertussis are
thought to be a combination of improved surveillance, improved
diagnostic methods, the emergence of more virulent Bordetella
(B.) pertussis strains as well as rapid waning of aPV-induced
immunity and the failure of current pertussis vaccines to prevent
infection and transmission on the longer term (3, 4).
Neither infection, nor any pertussis vaccine to date can
confer life-long protection against B. pertussis. However, several
different vaccine formulations are on the market that induce
different types of immune responses. The composition of multi-
component wPVs fluctuates between producers, and also the
available aPVs vary in the type, number, and concentration of
antigen components. For instance in Denmark, the wPV was
replaced in 1997 by a monocomponent aPV that solely contains
pertussis toxin (5). Antibody responses to pertussis toxoid and
pertussis toxin (PTx) are protective (6) and are used to monitor
pertussis vaccine- and B. pertussis infection-induced responses
(7). Anti-PTx antibodies alone have been shown to be sufficient
to protect against pertussis disease (8, 9).
Vaccine-induced antibody responses wane within 1–2 years
post-immunization (10, 11). However, little is known about
the differences in immune-response to subsequent B. pertussis
(re)infection years later (12). Moreover, it remains unknown
whether the vaccine given at childhood has an influence
on an infection-induced immune response in the years
after the expected protection has run out. Previously, it
was claimed that immune-responses to later B. pertussis
infection would be targeted at vaccine-antigens only and
not to the full spectrum of B. pertussis antigens, the so-
called “original antigenic sin” (13), and “linked epitope
suppression” (14), potentially leading to a skewed and impaired
antibody-response. Whether a distinct childhood immunization
program influences antibody responses following B. pertussis
reinfection several years later in life requires an in-depth
serological investigation.
B. pertussis infection-induced humoral responses have been
investigated in the past using enzyme-linked immunosorbent
assays (ELISA) or multiplex immunoassays (MIA) (11, 12,
15–17). However, in order to detect differences in the
complex and diverse antibody responses following a B. pertussis
infection, a broader approach is required. Valentini et al.
applied peptide microarray analysis to detect differences in
serum antibody recognition patterns induced by B. pertussis
infection and different pertussis vaccines (18). Furthermore,
a combination of two-dimensional electrophoresis (2DE) with
Western blotting was previously used for immunoproteomic
profiling of pertussis vaccine-induced and B. pertussis infection-
induced antibodies in mice (19, 20) as well as analysis of
human serological antibody responses to wPV vaccination
(21). These studies demonstrated a higher resolution of the
antibody response-patterns and therefore, an added value of the
application of 2DE for the unraveling of antibody profiles in
pertussis research.
In this study, we performed an in-depth serological
investigation of the antibody repertoire following a B. pertussis
infection in early adulthood looking at the dependence of vaccine
priming (wPV or a monovalent aPV) in infancy. To that end,
antigen specificity of IgG and IgA antibodies in sera of 36 Danish
individuals that were either vaccinated with aPV or wPV, was




Left-over material of serum submitted for diagnostic analysis in
the period 2014 to 2016 at Statens Serum Institut, Copenhagen,
Denmark was used. The sera had all been submitted for diagnosis
of pertussis by analysis of anti-PTx IgG (22). Information on the
sera is shown in Table 1. There are no clinical data available from
the individuals from whom the sera originated. Symptoms or
length of disease at the time of sampling are therefore unknown.
The study was approved by the National Committee on Health
Research Ethics, Denmark (H-16037386).
The pertussis vaccine used for the primary series in
Denmark changed in 1997 from a whole-cell to an acellular
monocomponent with pertussis toxoid as the sole pertussis
antigen. Sera were chosen from individuals from the wPV period
and the aPV period in equal numbers. In order to minimize any
differences between the groups due to age, the sera were selected
from individuals born just a few years prior (wPV group) or
after (aPV group) 1997. To increase the discriminatory power
of the study, sera were chosen to have either very low (≤15
IU/ml, the -group) or very high anti-PTx IgG levels (≥150 IU/ml,
the +group) in equal numbers. A total of 36 sera were chosen,
nine in each group designated as: wPV(+), wPV(–), aPV(+),
and aPV(–).
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TABLE 1 | Sample information of the included individuals and type of analysis performed on the serum.
Sample information Analysis

















IgG IgA IgG IgA IgG IgA
1 SSI-05 2016 Female 1999 16 6 3, 5, 12m + 5 y 12 X X X X X
2 SSI-08 2016 Male 1998 17 6 3, 5, 12m + 5 y 11 X X X X
3 SSI-25 2016 Female 1999 17 4 3, 5, 12m + 5 y 12 X X X X
4 SSI-26 2016 Female 1999 16 12 3, 5, 12m + 5 y 11 X X X X X
aPV low anti-PTx (aPV-) 5 SSI-27 2015 Female 1998 17 13 3, 5, 12m + 5 y 12 X X X X
6 SSI-28 2015 Female 1999 15 8 3, 5, 12m + 5 y 11 X X X X X
7 SSI-29 2015 Female 1998 16 9 3, 5, 12m + 5 y 12 X X X X X
8 SSI-34 2015 Female 2000 15 3 3, 5, 12m + 5 y 10 X X X X X X
9 SSI-35 2016 Female 2000 15 15 3, 5, 12m + 5 y 10 X X X X
Mean ± Stdev 16.0 ± 0.8
10 SSI-03 2016 Female 1994 21 3 X X X X X X
11 SSI-04 2016 Male 1994 22 3 X X X X
12 SSI-13 2016 Female 1995 21 12 X X X X
13 SSI-14 2016 Female 1995 20 3 X X X X
wPV low anti-PTx (wPV-) 14 SSI-15 2015 Female 1995 20 14 X X X X
15 SSI-16 2015 Male 1995 20 14 X X X X X
16 SSI-17 2015 Female 1995 20 9 X X X X X X
17 SSI-18 2015 Female 1995 20 9 X X X X X
18 SSI-19 2015 Male 1995 20 4 X X X X
Mean ± Stdev 20.4 ± 0.7
19 SSI-02 2016 Male 1999 16 ≥260 3, 5, 12m + 5 y 11 X X X X X X
20 SSI-06 2015 Male 1999 15 203 3, 5, 12m + 5 y 10 X X X X X X
21 SSI-20 2016 Female 1999 17 ≥260 3, 5, 12m + 5 y 12 X X X X
22 SSI-21 2016 Female 1999 16 229 3, 5, 12m + 5 y 12 X X X X
aPV high anti-PTx (aPV+) 23 SSI-22 2015 Male 1999 15 ≥260 3, 5, 12m + 5 y 11 X X X X
24 SSI-23 2015 Female 1999 16 ≥260 3, 5, 12m + 5 y 11 X X X X
25 SSI-24 2015 Male 1999 15 ≥260 3, 5, 12m + 5 y 10 X X X X X
26 SSI-32 2014 Female 1999 14 182 3, 5, 12m + 5 y 10 X X X X X
27 SSI-33 2014 Female 1998 15 ≥260 3, 5, 12m + 5 y 11 X X X X
Mean ± Stdev 15.4 ± 0.8
28 SSI-01 2015 Male 1995 19 ≥260 X X X X X
29 SSI-07 2015 Male 1995 20 151 X X X X X X
30 SSI-09 2016 Female 1995 21 196 X X X X
31 SSI-10 2016 Female 1995 20 ≥260 X X X X X
wPV high anti-PTx (wPV+) 32 SSI-11 2016 Female 1995 20 187 X X X X
33 SSI-12 2016 Female 1995 20 ≥260 X X X X
34 SSI-30 2014 Male 1994 19 ≥260 X X X X
35 SSI-31 2014 Male 1995 19 ≥260 X X X X X
36 SSI-36 2016 Male 1994 21 ≥260 X X X X X
Mean ± Stdev 19.9 ± 0.7
By using the Danish vaccination register (23), information
on received pertussis immunizations were collected for the
individuals from whom the sera originated. The register only
holds information from 1996 and onwards, and information
on immunizations is therefore, only available for the sera
from individuals in the aPV groups. Therefore, while the aPV
background is certain, the wPV background is only assumed, but
the vaccination coverage in Denmark has been high throughout
the period. Sera from the aPV group were selected to originate
from individuals who have received the full 3 + 5 + 12 months
+ 5 years vaccination series. The latest received vaccination was
thus ∼10 to 12 years prior to the serum sample being drawn,
i.e., after the presumed duration of immunity of the vaccine.
Sera from the wPV group were chosen from individuals with
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no registrations of having received an aPV, neither infant series
nor booster. There are no other recommendations for pertussis-
vaccinations in Denmark after the 5 year booster.
The vaccines used in Denmark in the period where the study
individuals were vaccinated were: infant series with a stand-alone
wPV (Statens Serum Institut, Denmark) until December 1996,
infant series with the acellularDiTeKiPol (Statens Serum Institut,
Denmark) from January 1997 and a pre-school booster at 5 years
of age with diTekiBooster (Statens Serum Institut, Denmark)
from September 2003.
Multiplex Immunoassay (MIA)
The levels of total IgA and IgG against filamentous hemagglutinin
(FHA) (Sigma Aldrich, Germany), combined fimbriae type 2
and 3 antigens (Fim2/3), pertactin (Prn), pertussis toxin (PTx)
(Biotrend, Germany), and outer membrane vesicles (OMV) of
B. pertussis strain B1917 (OMV B1917) in human sera were
determined using MIA. Conjugation of OMVs and purified
antigens to beads was performed as described previously (24).
Sera were diluted, 1,000-fold for total IgG and 100-fold for
IgA, in PBS (Thermo Fisher, Gibco, Netherlands) containing
0.1% Tween-20 (Sigma Aldrich, Merck, Germany) and 3%
bovine serum albumin (Sigma Aldrich, Merck, Germany). The
diluted sera were mixed 1 + 1 with 25 µl conjugated beads
(4,000 beads/(region/well)) and incubated for 30–45min at RT
at 600 rpm. Subsequently, samples were incubated with R-
Phycoerythrin (RPE)-conjugated anti-human IgA (1:100) and
IgG (1:1,000) and analyzed using the Bio-Plex System (Bio-Plex
200, BioRad, Netherlands). Samples were analyzed in singlets of
two different dilutions of which one was used for further analysis.
Antibody level results were depicted with GraphPad Prism
7.01 (GraphPad Software, Inc.), and presented in fluorescent
intensity (F.I.).
Sample Preparation for SDS-PAGE and
2D Electrophoresis
Bordetella pertussis B1917 was cultivated as described previously
(25) to obtain a bacterial lysate in the virulent state. Subsequently,
the bacteria were heat-inactivated at 56◦C for 30min. Of this
lysate, 500 µl was centrifuged (30min, 17,000 g) (HeraeusTM
PicoTM 17 Microcentrifuge, Thermo Fisher, Netherlands).
Supernatant was discarded and pellet was stored overnight
at −80◦C. Pellet was resolved in 500 µl Bacterial Protein
Extraction Reagent (BPER) (Thermo Fisher, Netherlands).
Protein concentration was determined using a Bicinchonicic acid
(BCA) assay (Thermo Fisher, Pierce, Netherlands). The antigen
composition of this lysate has been extensively investigated
previously with LC-MS (19).
Infrared Labeling
IR800 label (100 µg) (Licor, Westburg, Netherlands) was
dissolved in 25 µl distilled water. Subsequently, IR800 label
was conjugated to secondary antibodies by mixing 100 µl goat-
anti-human IgA (Southern Biotech, USA, Alabama) or rabbit-
anti-human IgG (Thermo Fisher, Netherlands) with 1 or 2
µl IR800 label, respectively. Unbound IR label was removed
from the samples using ZEBA spin desalting column (Thermo
Fisher, Netherlands).
SDS PAGE
An amount of 10 µg B. pertussis B1917 lysate (see sample
preparation) was incubated with 4× reducing sample buffer
(250mM Tris (Thermo Fisher, Merck, Netherlands), 8% SDS
(Sigma Aldrich, Germany), 400mM DTT (Sigma Aldrich,
Germany), 40% Glycerol (Sigma Aldrich, Germany), and 0.04%
bromophenol blue (Sigma Aldrich, Germany) 10min at 100◦C.
Sample was loaded on 10% NuPAGE bis tris 1.0mm precast
gel (Thermo Fisher, Invitrogen, Netherlands) and proteins were
separated with MES running buffer (Thermo Fisher, Invitrogen,
Netherlands), 200 Volt (V) for 45min in Xcell surelock minicell
system (Thermo Fisher, Invitrogen, Netherlands). Gel was either
stained with Coomassie (Imperial protein stain, Thermo Fisher,
Netherlands) or used for Western blot.
2D Electrophoresis
After the sample preparation, 50 µg B. pertussis B1917 lysate was
incubated for 30min at RT after adding 10 µl 250mM DTT,
0.62 µl IPG buffer pH 3–10 non-linear (NL), or IPG buffer pH
4-7 (GE Healthcare, Netherlands), and DeStreak Rehydration
Solution (GE Healthcare, Netherlands) to a final volume of 115
µl. Immobiline DryStrips pH 3–10 NL, 7 cm, or pH 4–7, 7 cm
(GE Healthcare, Netherlands) were rehydrated with sample in
an IPGbox (GE Healthcare, Netherlands). Isoelectric focusing
(IEF) was performed in the Ettan IPGphor three IEF system
(GE Healthcare, Netherlands) with the following program: 0.5 h
gradient to 300V, 1 h gradient to 1,000V, 1 h 2,000V, 1 h 3,000V,
1 h 4,000V, and 1 h 5,000V. After IEF strips were equilibrated
15min in 3mL equilibration buffer containing 75mM Tris-
HCl pH 8.8, 6M Urea (Sigma Aldrich, Merck, Germany), 30%
Glycerol, 2% SDS, bromophenol blue and 65mM DTT, followed
by a 15min equilibration with equilibration buffer containing
54mM iodoacetamide (Sigma Aldrich, Germany) instead of
65mM DTT. Strip was placed on a 4–12% NuPAGE bis-tris
Zoom gel (Thermo Fisher, Invitrogen, Netherlands) and sealed
with Agarose sealing buffer (BioRad, Netherlands). Proteins were
separated in MES running buffer in a Xcell surelock minicell
electrophoresis system for 50min at 200V. Gels were stained
with Coomassie or used for Western blot.
Western Blot
Nitrocellulose membrane (Thermo Fisher, Netherlands), filters
(BioRad, Netherlands), and gel were equilibrated in transfer
buffer consisting of 48mM Tris, 39mM Glycine (Sigma Aldrich.
Germany), 200mL 96% Ethanol (VWR, Merck, Netherlands)
in 1 L distilled water. Proteins were transferred from gel to
membrane in 60min, 60 mA/blot in the TE77 PWR semi-
dry transfer unit (Amersham Biosciences, United Kingdom).
Blot was blocked O/N at 4◦C in block buffer consisting of
0.1% PBS-T pH 7.2 (PBS pH 7.2 with 0.1% w/v Tween-20),
and 0.5% Protifar (Nutricia, Netherlands). Blot was incubated
for 2 h, while shaking with human sera diluted 1:1,000 in
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block buffer, followed by three times 5min wash with PBS-
T. Subsequently, the blot was incubated with 1:5,000 diluted
rabbit-anti-human IgG IR800 labeled or 1:5,000 goat-anti-
human IgA IR800 labeled in block buffer and incubated for 1 h
while shaking. Membranes were washed three times with 0.1%
PBS-T and scanned with the Odyssey infrared imager (Licor,
Westburg, Netherlands).
Delta2D Analysis
Western blots were analyzed using Delta2D version 4.7
(Decodon, Germany). Group warping strategy was used for
both IgG blots and IgA blots, meaning the four groups were
linked to each other [wPV(+), wPV(–), aPV(+), aPV(–)]
after the blots within the group were linked to each other.





The in-gel-digestion was performed as described previously
(19). For the LC-MS analysis, samples were analyzed by
nanoscale reversed-phase liquid chromatography electrospray
mass spectrometry, according to the method by Meiring et al.
(26). The analysis was performed on LTQ-Orbitrap XL mass
spectrometer (Thermo Fisher Scientific, Germany). Analytes
were loaded on a trapping column [Reprosil-Pur C18-AQ 5µm
(Dr. Maish, Germany); 23mm long × 100µm inner diameter]
with solvent A (0.1% (v/v) formic acid in LC-MS water) in
10min at 5 µL/min. The analytes were separated by reversed-
phase chromatography on an analytical column [Reprosil-Pur
C18-AQ 3µm (Dr. Maish, Germany); 36.2 cm long × 50µm
inner diameter] at a flow rate of 100–150 nL/min. A gradient was
started with solvent B [0.1% (v/v) formic acid in acetonitrile]:
7.5–57.5% in 25min and 85% for 10min. After the gradient,
the columns were equilibrated in 100% solvent A for 10min at
100–150 nL/min. The peptides were measured by data dependent
scanning; comprising a MS-scan (m/z 300–1,500) in the orbitrap
with a resolution of 60,000 (FWHM), followed by collision-
induced dissociation (LTQ) of the 10 most abundant ions of
the MS spectrum. The threshold value for these precursor ions
was set at 1,000 counts. The normalized collision energy was
set at 35% and isolation width at 2.0 Da, activation Q to 0.250
and activation time to 30ms. The maximum ion time (dwell
time) for MS scans was set to 250ms and for MS/MS scans to
1,000ms. Precursor ions with unknown and +1 charge states
were excluded for MS/MS analysis. Dynamic exclusion was
enabled (exclusion list with 500 entries) with repeat set to 1 and
an exclusion duration of 15 s. The background ion at 391.28428
Da was used as lock mass for internal calibration.
Proteome Discoverer 2.1 software was used for identification
of the peptide sequence data retrieved from LC-MS/MS spectra
as described in Raeven et al. (19). The gel spot was assigned to
one protein when intensities of this single protein was ≥70% of
the intensities of all identified proteins. The spot was not assigned
if the intensity of most abundant protein was <70%.
Statistical Analysis
Data were analyzed and visualized in R statistical software
(version 3.4.2). Differences in spot intensity were analyzed
by one-way ANOVA. Data were visualized using Principal
Component Analysis (PCA) and hierarchical clustering
(Euclidean distance, Ward.D linkage). Data from antibody MIAs
were log-transformed and statistically tested using a t-test. P ≤
0.05 were considered as significant differences.
RESULTS
Included Individuals
In total, sera from 36 Danish individuals were included in this
study. The samples were divided in four groups (n= 9) (Table 1)
based on a differentiation in immunization background (aPV
vs. wPV) and serum anti-PTx IgG levels (– vs. +) previously
measured with a diagnostic anti-PTx ELISA performed at Statens
Serum Institut. Since all included individuals received their last
pertussis immunization at least 10 years prior to the sampling
of blood, this indicates that the antibody responses analyzed
in this study are not vaccine-induced. The enhanced anti-PTx
responses are therefore, an indication of a recent or ongoing
B. pertussis infection.
Serum Antibody Levels
A MIA was performed to determine the serum IgG antibody
levels directed against PTx, Prn, FHA, and Fim2/3. Additionally,
beads coupled with pertussis OMVwere included to obtain semi-
quantitative data on antibody responses against other antigens.
Composition, identity, and concentration of the antigens, both
proteins and lipopolysaccharides (LPS), of these OMVs were
described previously (19).
The MIA data confirmed the significantly elevated anti-PTx
IgG levels in the wPV(+) and aPV(+) groups and the absence
of measurable anti-PTx IgG in the wPV(–) and aPV(–) groups
(Figure 1A). Individuals in the wPV(–) and aPV(–) groups had
low or absent antibody levels against FHA, Fim2/3, and Prn.
However, the anti-OMV responses were elevated in all groups.
The anti-OMV levels were significantly higher in the wPV(–)
group as compared to the aPV(–) group and significantly higher
in the high aPV(+) and wPV(+) groups as compared to their
low anti-PTx antibody counterparts. The anti-Prn and anti-FHA
IgG levels were, respectively, moderately and strongly enhanced
in high anti-PTx groups compared to the low anti-PTx groups.
A slight increase in anti-Fim2/3 IgG levels was observed in
the high anti-PTx groups and these levels were significantly
increased in the wPV(+) individuals as compared to the
aPV(+) individuals.
The MIA data demonstrated that IgA antibody levels against
PTx, OMV, Prn, FHA, and Fim2/3 were significantly enhanced in
the high anti-PTx groups compared to the low anti-PTx groups
(Figure 1B). No significant differences were observed between
the aPV- and wPV-immunized individuals with high anti-PTx
IgA levels. Whereas, anti-PTx IgA responses were absent in the
low anti-PTx groups, some individuals in these groups contained
low levels of anti-Prn IgA and most individuals had enhanced
anti-OMV and anti-FHA IgA levels. The anti-Fim2/3 IgA was
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FIGURE 1 | Serum IgG and IgA antibody responses. The (A) IgG and (B) IgA antibody levels against PTx, OMV, Prn, FHA, and Fim2/3 were determined in sera using
a MIA. Four groups (n = 9) were included with a distinct immunization background (aPV, wPV) and low (–) or high (+) serum anti-PTx IgG levels. Results are depicted
in fluorescence intensity (F.I.). Significant differences are indicated by *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 obtained using a t-test after
log-transformation of data.
significantly higher in the wPV(–) group as compared to the
aPV(–) group. In conclusion, the MIA results demonstrated
that individuals with high anti-PTx IgG titers also contained
high IgG and IgA antibody levels against FHA, Prn, and OMVs
but no significant differences were detected between individuals
vaccinated with aPV or wPV in childhood.
IgG and IgA Responses Determined With
1-Dimensional Electrophoresis
and Immunoblotting
A combination of 1-dimensional gel electrophoresis and
Western blotting (1DEWB) was used to profile the diversity
in antigen-specificity of serum IgG and IgA present in the
36 individuals with different immunization background
and PTx antibody-levels (Figures 2A,B). The profiling
was performed by comparing the location and intensity of
bands between the different individuals without quantifying
these parameters.
The analysis of IgG responses demonstrated that the number
and intensity of stained bands was higher in the two groups
with high anti-PTx levels compared to the two groups with low
anti-PTx levels (Figure 2A), which was in accordance with the
higher antibody levels measured with the MIA. The presence
of bands on the blots of the aPV(–) and wPV(–) group most
likely corresponded with the anti-OMV antibodies that were
detected with the MIA. Both the aPV(+) and wPV(+) groups
contained numerous bands that were detected in multiple
individuals within each group. Interestingly, this profiling
demonstrated that even within a group, where individuals
have the same immunization background, there was a large
diversity in antibody patterns following a B. pertussis infection.
For instance, antibody profiles of samples S2 and S32 in the
aPV(+) group were similar as were the patterns of sample
S33 and S23 or S24 and S20. However, when comparing the
patterns of (S2/S32), (S24/S20), and (S33/S23) they revealed
three distinct profiles. In the wPV(+) group the diversity was
even higher as only samples S1, S9, and S11 shared a common
antibody profile. Also for the serum IgA profiles the number
and intensity of bands was higher in the two groups with
high anti-PTx levels compared to the two groups with low
anti-PTx levels (Figure 2B). Some individuals in the aPV(–)
group (S5, S8, S29, S34, S35) and wPV(–) group (S3, S15, S17)
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FIGURE 2 | IgG and IgA responses determined with 1-Dimensional electrophoresis and immunoblotting on a B. pertussis B1917 lysate. (A) IgG and (B) IgA antibody
profiles were analyzed in sera of 36 individuals divided over four groups (n = 9) with a distinct immunization background (aPV, wPV) and low (–) or high (+) serum
anti-PTx IgG levels. Each group contains a marker lane (left) and nine blots representing single individual.
showed some pertussis-specific antibody responses that were
overall lower in the wPV(–) group. The comparison of responses
between the aPV(+) and wPV(+) groups revealed some overlap
in bands, but there was a large individual variation between
and within the groups. To conclude, the 1DEWB analysis
demonstrated the presence of a diverse range of antibodies in all
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FIGURE 3 | IgG responses determined with 2-Dimensional electrophoresis and immunoblotting. The presence and intensity of IgG antibodies were determined in sera
for 16 individuals divided over four groups (n = 4). (A) Total variance of component 1 (PC1) and component 2 (PC2) were calculated of the total IgG responses
analyzed by 2DEWB for each of the 16 individuals in the four groups. (B) The intensity of IgG responses of 133 spots were compared (red = higher, white = equal,
blue = lower) to a common reference (median of all intensities for each individual per spot). Euclidean clustering was performed to identify patterns in antibody profiles
for both the 16 individuals and the 133 spots. (C) Total variance of PC1 and PC2 were calculated of the significant IgG spots analyzed by 2DEWB for each of the 16
individuals in the four groups. (D) The intensity of the 40 spots that were found significant in the IgG response of all 16 individuals divided over four groups (n = 4)
were compared (red = higher, white = equal, blue = lower) to a common reference (median of all intensities for each individual per spot). Euclidean clustering was
performed to identify patterns in antibody profiles for both the 16 individuals and the 40 spots leading to three clusters (I–III).
groups but also a large variability in the response between and
within groups.
Profiling of Serum Antibody Responses
Using 2-Dimensional Electrophoresis (2DE)
Proteins in a B. pertussis B1917 lysate were separated with 2DE
(Supplementary Figure 1) to achieve better a protein separation
on the gel, thereby enhancing the chance of antigen identification
with LC-MS. The 2DE gels were subsequently combined with
immunoblotting (2DWB). For this 2DWB analysis, a selection of
serum samples were included (Table 1) for antibody profiling of
IgG (4 × 4 samples) and IgA (4 × 2 samples). The selection of
samples was based on the most intense signal per group within
the 1DWB analysis (Figures 2A,B).
For IgG, 16 sera were used for immunoblotting
(Supplementary Figure 2). Using Delta2D, a warping strategy
was applied to make an overlay of the 16 individual blots
and to perform spot detection. This resulted in 133 unique
immunogenic protein spots. Subsequently, intensities of all
133 spots were determined for each spot on each gel, which
were then compared in a principle component analysis (PCA)
(Figure 3A). The PCA demonstrated a similar response between
aPV(–) and wPV(–) groups. Furthermore, both aPV(+) and
wPV(+) groups showed more variance compared to groups
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with low anti-PTx levels. However, the aPV(+) group responded
differently compared to the wPV(+) group. Moreover, a large
variation was observed between individuals in the wPV(+)
group. Especially, sample S36 of the wPV(+) group seemed to
cluster together with the samples of the aPV(+) group. Next,
the spot intensity of each of the 133 immunogenic proteins
were compared to a common reference (the mean of the
spot intensities for all 16 sera for each individual spot) and
summarized in a heatmap (Figure 3B). An Euclidean clustering
was performed on all 133 spots but also on the 16 sera in
order to identify patterns in antibody profiles and individuals.
This analysis confirmed the clustering based on the 16 sera
as observed in the PCA plot where the aPV(+) and wPV(+)
groups showed distinct response patterns, while sample S36
showed a large variation compared to the other samples in the
wPV(+) group.
In total, 40 of the 133 spots were considered to be significant
IgG responses [one-way ANOVA, false discovery rate (FDR)
of 10%]. A PCA of these 40 significant immunogenic proteins
revealed a similar yet even more distinct separation between
the different groups as was observed for the analysis on
all 133 spots (Figure 3C). The aPV(–) and wPV(–) groups
clustered together indicating no difference in response. However,
the aPV(+) and wPV(+) groups showed a large variance
compared to the aPV(–) and wPV(–) groups but also when
compared to each other. Within this analysis of 40 proteins,
the variation between individuals of each group was much
lower as compared to the PCA of all 133 immunogenic
proteins. Based on Euclidean clustering on both the expression
pattern within each individual and the intensity of the 40
spots as compared to the common reference, three different
clusters (I–III) could be identified (Figure 3D). The proteins
in cluster I showed antibody binding to both the wPV(+)
and aPV(+) groups, which was higher in the wPV(+) group.
The immunogenic proteins in cluster II did solely bind to
antibodies detected in the wPV(+) group, whereas for cluster
III this was exclusively found for samples from the aPV(+)
group. Of these 40 spots, 17 spots could be identified using
in-gel-digestion and LC-MS (Table 2). Cluster I contained
well-known immunogenic pertussis antigens, such as Vag8,
Prn, and FHA. However, also the TonB-dependent outer
membrane receptor and the iron-dependent enzyme aconitate
hydratase were identified in cluster I. Protein identification in
cluster II turned out to be more challenging as only GroEL
and Dihydrolipoyllysine-residue succinyltransferase component
of 2-oxoglutarate dehydrogenase complex (odhB) could be
successfully identified leaving nine proteins unidentified. Almost
all other immunogenic spots in this cluster were found in the
pI range of 3–7. The resolution of the protein separation in this
region was too low to perform a reliable protein identification.
Finally, the proteins in cluster III remained mainly unidentified,
except for protein translocation subunit SecA. SecA is a protein
that is involved in translocation of proteins across the inner
membrane such as FHA (27). In order to enhance the chance
of identifying immunogenic proteins in cluster II we decided to
perform 2DE with an altered pI range that led to a better protein
separation in the pI range 4–7 (Supplementary Figure 3A).
Next, this gel was used to perform a Western blot using a single
representative serum (sample S7) from the wPV(+) group
as this group showed the most intense antibody binding to
antigens in cluster II (Supplementary Figure 3B). This resulted
in identification of peptidoglycan associated protein (PAL) and
confirmed the identification of Dihydrolipoyllysine-residue
succinyltransferase component of 2-oxoglutarate dehydrogenase
complex (Supplementary Table 1). Moreover, a characteristic
pattern was observed between 40 to 50 kDa and around pI 5 to 6
in samples S7, S16, S28, and S31 (Supplementary Figure 2). This
pattern was also observed when analyzing sample S7 on a gel with
a pI range 4–7 (Green antigens in Supplementary Figure 3B
and Supplementary Table 1). LC-MS identification
demonstrated that a large number of these spots contained
GroEL fragments.
For IgA, eight sera were used for immunoblotting
(Supplementary Figure 4). The warping strategy and spot
detection using Delta2D resulted in 47 unique immunogenic
protein spots. As for the IgG analysis, the spot intensities
of all 47 spots were obtained of each spot on each gel and
subsequently compared in a PCA (Figure 4A). Here, a clustering
was observed based on immunization background as the wPV
groups clustered together. The aPV groups clustered together,
except for sample S2. The spot intensities of the 47 immunogenic
proteins were compared to a common reference and summarized
in a heatmap (Figure 4B). An Euclidean clustering, performed
on all 47 spots as well as the eight samples, revealed that only
the wPV(+) samples S1 and S7 clustered together while the
rest contained a different profile. The separate clustering of
sample S2 from the rest was due to an intense cluster of spots
exclusively present in this sample. Of the 47 spots, seven were
considered to represent significant IgA responses (one-way
ANOVA, false discovery rate (FDR) of 20%). Using these data,
the aPV(+) and wPV(+) groups revealed distinct variance
in the PCA (Figure 4C). Four distinct clusters (I–IV) were
observed in a heatmap (Figure 4D) and unraveling the identity
of the seven significant spots was attempted using LC-MS
(Table 3). Cluster I contained two immunogenic proteins present
in both aPV groups, with highest intensity in the aPV(+)
group. One immunogenic protein was found in cluster II that
showed antibody-responses in both aPV groups, but with the
highest intensity in the aPV(–) group. Cluster III included
one immunogenic protein with antibody-responses solely
present in the wPV(–) group. Finally, the three immunogenic
proteins of cluster IV were all identified as pertactin and
antibody-responses were intensely and exclusively present
in the wPV(+) group. All other immunogenic IgA proteins
remained unidentified.
In conclusion, the 2DEWB antibody profiling revealed many
previously unidentified immunogenic antigens induced by a
B. pertussis infection. Some antigens could be identified, while
others remained unidentified. A selection of these immunogenic
antigens were significantly different between aPV and wPV
groups and may therefore be related to the type of pertussis
vaccine received in childhood.
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TABLE 2 | Significant IgG responses following a B. pertussis infection in wPV and aPV immunized individuals.
Cluster Protein* ID Accesion
number




I Pertactin autotransporter prn P14283 93.4 9.2 14.6 9
Pertactin autotransporter prn P14283 93.4 9.2 14.6 9
<70% confident pertussis toxin
subunit 1 based on 4-7 strip
Autotransporter Vag8 Q79GN7 94.8 6.8 63.7 43





ABC47_15525 A0A1P9PLY0 77.8 6.6 43.6 30
TonB-dependent outer membrane
receptor
ABC47_15525 A0A1P9PLY0 77.8 6.6 40.4 23
TonB-dependent outer membrane
receptor
ABC47_15525 A0A1P9PLY0 77.8 6.6 40.4 23
U3




ABC47_15525 A0A1P9PLY0 77.8 6.6 40.4 23







associated protein based on 4–7 strip
Dsc of 2-odc*** odhB Q7VZ17 41.8 5.5 67.6 16
Dsc of 2-odc*** odhB Q7VZ17 41.8 5.5 76.7 19
Dsc of 2-odc*** odhB Q7VZ17 41.8 5.5 67.6 16
U11**




60kD chaperonin GroEL P48210 57.4 5.2 53.2 28
III Protein translocase subunit SecA SecA Q7VUR2 103.2 5.7 52.5 36
Protein translocase subunit SecA SecA Q7VUR2 103.2 5.7 52.5 36
Protein translocase subunit SecA SecA Q7VUR2 103.2 5.7 52.5 36
U14 < 70% confident
Carbomoyl-phosphate synthase










**Green spots (10–24) represent a series of spots all involving the antigen GroEL.
***Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex.
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FIGURE 4 | IgA responses determined with 2-Dimensional electrophoresis and immunoblotting. The presence and intensity of IgA antibodies were determined in sera
for eight individuals divided over four groups (n = 4). (A) Total variance of component 1 (PC1) and component 2 (PC2) were calculated of the total IgA responses
analyzed by 2DEWB for each of the eight individuals in the four groups. (B) The intensity of IgA responses of 47 spots were compared (red = higher, white = equal,
blue = lower) to a common reference (median of all intensities for each individual per spot). Euclidean clustering was performed to identify patterns in antibody profiles
for both the eight individuals and the 47 spots. (C) Total variance of PC1 and PC2 were calculated of the significant IgA spots analyzed by 2DEWB for each of the
eight individuals in the four groups. (D) The intensity of the seven spots (including the unidentified proteins U23–U26) that were found significant in the IgG response of
all eight individuals divided over four groups (n = 4) were compared (red = higher, white = equal, blue = lower) to a common reference (median of all intensities for
each individual per spot). Euclidean clustering was performed to identify patterns in antibody profiles for both the 8 individuals and the seven spots leading to four
clusters (I–IV).
DISCUSSION
The B. pertussis resurgence is targeting the unvaccinated
population, but is also observed within the vaccinated
population. In Denmark, the wPV was replaced in 1997 by
a monocomponent aPV that solely contains pertussis toxoid (5).
The efficacy of this aPV is high (28) and it can potentially be
implemented for maternal immunization (9) making it a suitable
vaccine to protect infants. However, data from recent years
demonstrate that, despite a high vaccine coverage, the pertussis
resurgence is also taking place in Denmark (5, 29, 30). The
resurgence is however thought to be primarily due to increased
diagnostic repertoire and improved awareness. The current
situation provides two distinct groups in the Danish population
with a different priming immunization (aPV or wPV). It was
recently demonstrated that T-helper cell polarization persists
following whole-cell pertussis vaccination despite repeated
acellular boosters (31) Because prime immunization may also
have an effect on the infection-induced antibody response,
we investigated the immunoproteomic profiles in distinct
groups with different vaccination backgrounds within the
Danish population.
We have shown that the antibody specificity to B. pertussis
antigens as a result of a recent pertussis infection in adolescence is
correlated with the pertussis vaccine received in childhood.While
the available material only allows for investigation of antibody
responses, there could possibly also be differences between the
aPV and wPV groups when it comes to number or type of
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TABLE 3 | Significant IgA responses following a B. pertussis infection in wPV and aPV immunized individuals.





IV Pertactin autotransporter Prn P14283 93.4 9.2 14.6 9
Pertactin autotransporter Prn P14283 93.4 9.2 14.6 9
Pertactin autotransporter Prn P14283 93.4 9.2 14.6 9
*U, unidentified proteins.
B-cells following infection. Moreover, as the analysis of serum
IgA responses on 2DEWB was only performed with two samples
for each group, the power of these results is limited and only give
an indication of antigens involved. As these serum IgA responses
are only a reflection of the IgA responses at mucosal sites, a
direct analysis of these responses in lung lavages or nasal swabs
could give a better indication. The current study did however
show different antibody patterns when comparing sera from
individuals having received the whole-cell vaccine to sera from
individuals who had received the acellular vaccine. The sera from
whole-cell vaccinated individuals contained antibody responses
to more different B. pertussis antigens. The antibody response
to well-known immunogenic antigens such as FHA, Prn, and
Vag8 (32) as well as other antigens such as a TonB-dependent
outer membrane receptor (33) and the iron-dependent enzyme
aconitate hydratase was more abundant in the wPV(+) group.
Antibodies against cytosolic antigens such as GroEL and odhB
was exclusively detected in the wPV(+) group. As these antigens
are also present in the wPV this could resemble a recall memory
response induced by vaccination. However, the discovery of
antibodies to SecA (27) as well as those against ten unidentified
antigens that were found exclusively in the aPV(+) group cannot
be directed to a vaccine-induced memory response given that
the aPV only contains pertussis toxoid. These findings may
indicate that the B. pertussis infection is processed differently
between individuals immunized with wPV or aPV in childhood
leading to a distinct infection-induced antibody response.
It would be interesting to determine whether immunization
background also influences the severity of the disease in
infected individuals. Unfortunately, additional information such
as duration or severity of symptoms for these individuals was
not available.
The Danish aPV is without remnants of other proteins from
B. pertussis (34). If the aPV groups have had previous contact
with other B. pertussis antigens than PTx, it is therefore, not
originating from the vaccine. Moreover, antibody response after
vaccination wane after 15 months to 2 years after immunization,
to levels below detection (10, 11). A limitation to the study is that
information on the infant pertussis immunizations for the wPV
group was unknown. However, as the vaccination coverage in
Denmark has been high throughout the whole period we assume
that most of these individuals have been wPV vaccinated. The
main focus, to identify if childhood aPV changes subsequent
immune responses, is not hampered by this since the vaccination
status of all in the aPV group is known. Also the aPV(+)
and wPV(+) groups had an ongoing or recent pertussis with
infection-induced anti-PTx antibodies as opposed to vaccine-
induced antibodies, since (i) there are no recommendations for
adolescent or adult pertussis vaccinations in Denmark, (ii) the
Danish vaccination registry also contains information on adult
immunizations and none was listed, and (iii) the sera were
submitted for diagnostic purposes. The aPV and wPV groups
differ slightly by age, as individuals in the wPV group are ∼4
years older than in the aPV group. However, as all of them have
grown up during the same period and in the same country, we
feel confident that these groups are comparable when it comes
to antibody-repertoire.
We have demonstrated that the antibody-response during B.
pertussis infection is not limited to the antigens contained in the
childhood vaccine, since individuals who had been vaccinated
with a monocomponent pertussis toxoid vaccine in childhood
showed increased IgG and IgA responses to OMV, Prn, FHA,
and Fim2/3 at ongoing pertussis. Two previous papers have
claimed that due to vaccination background, the responses to
a B. pertussis infection are limited to the antigens present in
the vaccine (13, 14). However, these studies described infections
occurring in the follow-up time of clinical trials, respectively, 15
months (35), 2 years (36), 3.5 years (37), and ∼3 years (13). This
indicates that for all the individuals in these older studies, the
B. pertussis infection occurred within the timeframe in which
the vaccine-induced immunity should not have waned fully.
Those cases could therefore be regarded as “vaccine failures.”
On the other hand, the pertussis cases in the present study
occurred more than 9 years after the last pertussis vaccination,
so the protective effect of the vaccine-induced immunity is
expected to be low or to have completely waned. The difference
between the observations between the previous and present study
could possibly be a difference in the immune-response between
individuals in which the vaccine might have failed to induce
a proper immune response and individuals where the vaccine
protected as intended. The question is whether there in fact was
a “linked-epitope suppression” or “original antigenic sin effect”
in the previous studies or if the observations were caused by
other factors. The simplest explanation can be the difference in
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response between first or second encounter with an antigen: the
individuals with vaccine-failures in the older studies only showed
brisk secondary immune-responses to the previously recognized
vaccine-antigens, while responses to other antigens gave a less
pronounced primary response. A different explanation to the
older observations could also be an underlying immunological
defect in some of the children leading to the actual vaccine
failure and therefore an aberrant immune response. For one of
the previous studies, the comparison of antibodies at ongoing
pertussis were made between 8 and 16 year old unvaccinated
children and 13–36 months old children that got infected though
they were vaccinated 2 years, or less, before, with the older
children showing the highest antibody-responses. The observed
differences in that study could therefore be a simple effect of
different age, and in particular that the older children in the
study had most likely met cross-reacting antigens while growing
up, thus giving rise to a strong secondary response at infection
compared to the younger children that got infected despite being
recently vaccinated.
The applied immunoproteomic profiling has become an
important tool to determine antibody responses in pertussis
research as was demonstrated for responses after pertussis
infection (15, 19, 25, 38, 39) and after immunization with
different pertussis vaccines (19–21). Previous studies that have
implemented 2DE for pertussis research used either Tohama,
Saadet (38, 40), the Chinese WCV strain 58003 (21) or varied
with the antigen content as a result of iron starvation (41).
Prior to the current study it was unfortunately not possible to
retrieve information about which B. pertussis strain(s) infected
the individuals included in this study. It is important to realize
that the use of a different strain, and more importantly, different
growth conditions could affect the antigen composition of the
lysate used for Western blotting. This could have an influence
on the outcome of the results of antibody profiling. In this
study we included the B. pertussis B1917 strain, a Dutch clinical
isolate from 2000 that is closely related to the current circulating
strains globally (42) and the growth conditions were chosen
to maximize the expression of virulence factors. The antigen
composition of this lysate has been characterized in detail before,
confirming the virulent state of the bacteria (19). While this
strategy reduces the risk of a mismatch between the antigen
composition of the lysate and the antibodies in the serum to a
minimum, this method cannot guarantee that some potentially
immunogenic antigens were missed. For a few of the individuals
in the groups with low anti-PTx antibodies (wPV– and aPV–),
an elevated antibody response to OMV, Prn, FHA, or Fim2/3
was observed, sometimes in the same individual. Given the large
variance in these antibodies, the high levels of antibodies are
caused by either (i) a previous B. pertussis infection where anti-
PTx antibodies have waned, (ii) cross-reacting antibodies from
other recent or ongoing infections with other Bordetellae (43), or
(iii) cross-reacting antibodies from recent or ongoing infections
with bacteria who display surface proteins similar to B. pertussis
such as has been demonstrated for FHA (44, 45). This pattern
emphasizes the relevance of recommendations for using solely
anti-PTx serology for diagnostic purposes of B. pertussis due to
the high specificity of these antibodies (46). For future clinical
studies involving pertussis vaccines or a B. pertussis human
challenge model (47) it is crucial to investigate pre-existing
antibody profiles as these can influence the outcome of such
studies. For instance in the clinical phase I study investigating
the live-attenuated pertussis vaccine BPZE1, investigators used
anti-PTx IgG levels as pre-screening parameters to exclude
individuals. Afterwards, high pre-existing anti-Prn IgG levels
were found to be influencing the required colonization of the
vaccine and therefore, the efficacy (48). This demonstrates the
requirement of a complete profiling of individuals within clinical
studies to prevent confounding of results. The current method
could be used to obtain these profiles and therefore providing a
valuable tool for pertussis research.
In conclusion, this antibody profiling approach with 2D gel
electrophoresis allowed to differentiate B. pertussis infection-
induced antibody responses in adolescents and young adults
with distinct childhood immunization background. Importantly,
this study showed that the antibody responses in individuals
immunized with a monocomponent pertussis toxoid only aPV
in childhood were not limited to anti-PTx alone. Overall, we
demonstrated that the type of childhood pertussis immunization
give rise to distinct antibody responses following a B. pertussis
infection later in life. Future studies could focus on whether
this difference in response could also be related to severity
of disease or particular symptoms as a result of the different
immunization background.
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Supplementary Figure 1 | Coomassie staining of B. pertussis B1917 bacterial
lysate separated with 2DE. Coomassie staining of B. pertussis B1917 separated
on a 2DE gel with a pI 3–10 NL range.
Supplementary Figure 2 | IgG responses determined with 2-Dimensional
electrophoresis and immunoblotting. Sera of 16 selected individuals divided over
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four groups (n = 4) with a distinct immunization background (aPV, wPV) and low
(–) or high (+) serum anti-PTx IgG levels were analyzed for IgG antibody profiles on
a B. pertussis B1917 lysate separated with 2DE. Each blot represents one
individual and contains a size marker (left).
Supplementary Figure 3 | Bordetella pertussis B1917 antigen profile on a pI 4–7
range and IgG immunoproteomic profile. (A) Coomassie staining of B. pertussis
B1917 separated on a 2DE gel with a pI 4–7 range. This gel was used for (B)
Western blotting with serum of sample S7 leading to a immunoproteomic profile
including two known antigens (GroEL, Prn) and 36 unknown antigens that were
further identified with LC-MS as shown in Supplementary Table 1. Green spots
represent a series of spots involving GroEL.
Supplementary Figure 4 | IgA responses determined with 2-Dimensional
electrophoresis and immunoblotting. Sera of eight selected individuals divided
over four groups (n = 2) with a distinct immunization background (aPV, wPV) and
low (–) or high (+) serum anti-PTx IgG levels were analyzed for IgA antibody
profiles on a B. pertussis B1917 lysate separated with 2DE. Each blot represents
one individual and contains a size marker (left).
Supplementary Table 1 | IgG response on pI 4-7 gel.
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